新冠肺炎 / COVID-19

SKU Rehab0095
HK$909.00
In stock
1
Product Details

如你有此疾病,請遵照閣下醫生的完整醫療方案;而是否使用多學科復康方案前,你必須咨詢主診醫生的意見,如果閣下的主診醫生不建議您加入補充劑調理組合,請你不要使用。如果你需要尋求其他醫生作第二咨詢,閣下可聯絡我們線上<無邊界醫生>或你自己城市內的其他專業醫生的再診斷。

新冠肺炎

新型冠狀病毒SARS-CoV-2是世界衛生組織(WHO)於2020年2月11日命名為COVID-19的高致病性β-冠狀病毒之一。早期診斷COVID-19是治療感染最關鍵的步驟。診斷工具通常是分子方法、血清學和病毒培養。近年來,基於CRISPR的方法被用於診斷和治療冠狀病毒感染。2019年流感季節nCoV的出現,導致口服和靜脈注射的抗生素和神經氨酸酶抑制劑的廣泛使用。

現時,SARS和MERS刺突蛋白的抗病毒抑制劑、神經氨酸酶抑制劑、抗炎藥和EK1肽是SARS-CoV-2感染者可用的治療選擇。此外,此前用於治療瘧疾和自身免疫性疾病的氯喹在2019年的nCoV感染治療中也顯示出療效。在嚴重低氧血症時,聯合應用抗生素、α-干擾素、洛匹那韋和機械通氣可有效緩解症狀。全面瞭解先天性和適應性免疫反應,將有可能提出有效的抗病毒藥物及其有效的治療措施,以防止病毒感染。這種治療策略將有助於全世界的患者保護自己免受嚴重和致命的病毒感染,這種病毒感染可能會演變和產生耐藥性,並降低死亡率。

Ref: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC75138...

新冠肺炎-多學科研證復康方案

  • 藥物及其他醫療方案,請遵醫從醫生建議
  • 飲食營養請依營養師指引
  • 運動及或心理輔導,請參考各專家建議
  • 為免錯誤診斷及漏診,請上傳最近一個月醫院的專業診斷報告,如證實是此症,則可參加試用期不如意退款計劃#。

可能適合的補充劑支援:

標準組合:

  • 試用時期: 2星期

# <試用期不如意退款計劃>,請參考相關文件

本產品並非根據《藥劑業及毒藥條例》或《中醫藥條例》注册。任何對其提出的索賠均不受此類登記評估的約束。本產品不用於診斷、治療或預防任何疾病。

If you have this disease, please follow your doctor's complete medical plan. You must consult the attending doctor before using the multidisciplinary rehabilitation plan. If your attending doctor does not recommend you to join the supplement conditioning combination, please do not use it. If you need to seek second opinion from other doctors, you can contact our online "Doctors Without Borders", or another professional doctor in your own city.

Novel coronavirus SARS-CoV-2, designated as COVID-19 by the World Health Organization (WHO) on the February 11, 2020, is one of the highly pathogenic β‐coronaviruses which infects human. Early diagnosis of COVID-19 is the most critical step to treat infection. The diagnostic tools are generally molecular methods, serology and viral culture. Recently CRISPR-based method has been investigated to diagnose and treat coronavirus infection. The emergence of 2019-nCoV during the influenza season, has led to the extensive use of antibiotics and neuraminidase enzyme inhibitors, taken orally and intravenously.


COVID-19


Currently, antiviral inhibitors of SARS and MERS spike proteins, neuraminidase inhibitors, anti-inflammatory drugs and EK1 peptide are the available therapeutic options for SARS-CoV-2 infected individuals. In addition, Chloroquine, which was previously used for malarial and autoimmune disease, has shown efficacy in the 2019-nCoV infection treatment. In severe hypoxaemia, a combination of antibiotics, α-interferon, lopinavir and mechanical ventilation can effectively mitigate the symptoms. Comprehensive knowledge on the innate and adaptive immune responses, will make it possible to propose potent antiviral drugs with their effective therapeutic measures for the prevention of viral infection. This therapeutic strategy will help patients worldwide to protect themselves against severe and fatal viral infections, that potentially can evolve and develop drug resistance, and to reduce mortality rates.

Ref: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC75138...

Multidisciplinary research and rehabilitation program for COVID-19

  • Please follow the doctor's advice for drugs and other medical plans
  • Please follow the guidance of nutritionist
  • For sports or psychological counseling, please refer to the experts' suggestions
  • In order to avoid misdiagnosis and missed diagnosis, please upload the professional diagnosis report of the hospital in the latest month. If it is confirmed to be this disease, you can participate in the .#

Possible supplements supporting:

Standard combination:

Trial period: 2 weeks

# Please refer to the relevant documents for the

Products are not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.

Save this product for later